Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 33
Summary
- Conditions
- Prostate Adenocarcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Only males
Description
OUTLINE: Patients receive apalutamide orally (PO) once daily (QD) for 90 days in the absence of disease progression or unacceptable toxicity. After completion of the study treatment, patients are followed up at 180, 365, 545, and 730 days; and at years 3, 4 and 5 by medical record review.
OUTLINE: Patients receive apalutamide orally (PO) once daily (QD) for 90 days in the absence of disease progression or unacceptable toxicity. After completion of the study treatment, patients are followed up at 180, 365, 545, and 730 days; and at years 3, 4 and 5 by medical record review.
Tracking Information
- NCT #
- NCT02721979
- Collaborators
- Janssen Scientific Affairs, LLC
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Michael Schweizer Fred Hutch/University of Washington Cancer Consortium
Get Well Soon